Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study of Juluca versus continued antiretroviral therapy in virologically suppressed HIV-1 patients with K103N mutation
2017-004040-38Phase 3Unknown
- Sponsor
- NEAT ID Foundation
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir + rilpivirine, dolutegravir and rilpivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by NEAT ID Foundation. Primary endpoint: Virological suppression at week 48. Status: unknown.
02
Drugs
dolutegravir + rilpivirinedolutegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-004040-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004040-38.